Viva Biotech Holdings · HKEX:1873
Viva Biotech — FY2023 Earnings Presentation
31 slides from Viva Biotech's earnings presentation, Mar 29, 2024
Slide 1: Viva Biotech 2023 Annual Results
Viva Biotech 2023 Annual Results 29 March 2024 Shanghai, China
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain information set forth in this presentation contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our managemen
Slide 3: Contents
01 Business Highlights 02 Financial Performance CONTENTS 03 Future Strategies Q&A Session
Slide 4: Part 1: Business Highlights
Viva PART 1: Business Highlights
Slide 5: World Leading One-stop Drug Research and Production Platform
World Leading One-stop Drug Research and Production Platform CRO Business CDMO Research and Production Investment & Incubation Business Business Focus on FIC's Discover business, take Provide innovative drug partners with Focus on discovering and investing in SBDD as the core to drive FBDD, drug sma
Slide 6: Structure of Viva Biotech Group
Structure of Viva Biotech Group Viva Biotech Holdings (1873.HK) 10.87% Strategic Investors 73.66% 100% 100% 26.34% Small Molecule Incubator CRO CDMO 100% 100% 100% Shanghai Suzhou Chengdu Overseas Ningbo Taizhou Onshore Equity Offshore Jiaxing Shanghai Incubator Holding Equity Holding Platform Platf
Slide 7: Integrated Platform for Comprehensive Drug R&D and Manufacturing Services
Integrated Platform for Comprehensive Drug R&D and Manufacturing Services Affinity-Based Drug Screening Drug Metabolism Mass Spectrometry (ASMS, INTACT-MS) SPR (ADME/DMPK) Crystal Soaking Protein Science and V-DEL Structural Research Compound Library (Covalent Compounds, Fragments, Structural Divers
Slide 8: Overview
Overview Business Highlights RMB million Full-Year revenue in 2023 reached RMB 2,155.6 million, -9.4% YOY Gross profit reached RMB 738.5 million, -9.5% YOY Adjusted net profit reached RMB 208.8 million, a significant turnaround compared to the corresponding Period of last year Adjusted non-I
Slide 9: Overview: CRO Business
Overview CRO Business: Attractive Outlook in the Long Run Despite Slight Fluctuation in the Short Term 54.1 Revenue: RMB 844.9 million, -5.6% YOY 12 Gross Profit: RMB 363.7 million, -8.5% YOY 85.8 Top 10 Customer Revenue Contribution: 25.7% Revenue from Overseas Clients: 87.1%, YoY decrease
Slide 10: CRO Business: Continuous Optimization of Personnel and Steady Growth in Client Numbers
CRO Business: Continuous Optimization of Personnel and Steady Growth in Client Numbers Serving Global Leading Continued Optimization of CRO R&D Personnel Pharmaceutical Enterprises 2023 1155 2022 1617 2021 1211 Based on Total Annual Revenue in 2023 Number of CRO Clients: +14.2% YOY 2023 1398 Out of
Slide 11: CRO Business: Steady Operations with Continued Increase in Target and Protein Structure Deliveries
CRO Business: Steady Operations with Continued Increase in Target and Protein Structure Deliveries Radiation Source Usage Hours Number of Target and Protein Structure Deliveries 2023 2059 2022 2064 Independent Target Research: +8 YOY 2021 1934 Maintaining long-term cooperation with 13 global syn
Slide 12: Combining AI Technology with Experimental Approaches to Revolutionize Drug Discovery
Combining AI Technology with Experimental Approaches to Revolutionize Drug Discovery Computation: Virtual Screening with Machine Learning-based AI Structure Prediction Active Learning Free Energy Perturbation ADMET Prediction Experiment: Viva Structural Biology Viva Drug Screening Platform Viva Medi
Slide 13: Overview: CDMO R&D and Production Services
Overview CDMO R&D and Production Services Revenue of Langhua Pharmaceutical: RMB 1310.7 million, -11.7% YOY Adjusted Gross Profit of Langhua Pharmaceutical: RMB 388.8 million, -10.1% YOY 305 261 CDMO: Revenue RMB 734.7 million, -17.0% YOY; adjusted gross profit margin 295 38.83%, +0.41pp YOY 3
Slide 14: CDMO Business: Front-end Funnel Effect and Capacity Building
CDMO Business: The front-end funnel effect continues to manifest, while capacity building continues to strengthen Revenue and Gross Profit from CDMO RMB Million 885 734.7 340 285 2022 2023 Revenue Adjusted gross profit margin Revenue from CDMO: RMB 734.7 million，decreased by 17.0% YOY, which was p
Slide 15: Langhua Factory's Capacity Building Status
Langhua Factory’s Capacity Building Status: Production capacity expansion plan (23-25E) Cubic metre 2025E 1260 2024E 860 2023 860 C 1 A1 B 1 In addition, Langhua Pharmaceuticals plans to establish a new production capacity of 400 cubic meters in 2024 and 2025. The civil engineering project is curr
Slide 16: Continuous strengthening of CMC capacity, with a constant increase in the number of projects
Continuous strengthening of CMC capacity, with a constant increase in the number of projects Revenue Scale RMB CMC Staff ～RMB 56 million 2023 113 ～RMB 50 million 2022 155 2021 120 ～RMB 10 million Historical Trends in the Cumulative Number of CMC Projects 2023 183 2021 2022 2023 Internal and External
Slide 17: Overview: EFS Investment & Incubation Business
Overview EFS Investment & Incubation Business RMB million In 2023, one new portfolio company was added, obtained through 1419 stock-for-stock exchange 1290.3 1241.3 As at December 31, 2023, the Group had invested in a total of 92 portfolio companies 1152.5 1100.7 During the Reporting Period, 6
Slide 18: VBI Business
VBI Business In 2023, VBI had invested in a total of 92 portfolio companies. One startup company was newly invested and incubated, obtained through a stock-for-stock exchange. In 2023, the Company achieved complete or partial investment exits from 6 incubation portfolio companies. New Project Ex
Slide 19: 222 Pipeline Projects in Portfolio Companies
Continuous Expansion of Drug Pipeline, with Ongoing Financing Progress • VVN001 initiated phase III clinical trial • VVN539 completed phase II clinical trial in the 222 Pipeline Projects in Portfolio Companies • United States VVN461 advanced to phase II clinical trial *Calculated Based on the Cumula
Slide 20: Key Projects in VBI Investment Portfolio
Key Projects in VBI Investment Portfolio No. Name Country Mechanism Indication Pipeline Stage Company Overview Dogma has discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species. Guided by dozens of high-resolution x-ray struct
Slide 21: Part 2: Financial Performance
PART 2: Financial Performance
Slide 22: Financial Performance of the Group
Financial Performance of the Group Revenue of the Group RMB million Adjusted Gross Profit RMB million 2380 831 752.7 2155.6 2022 2023 2022 2023 Adjusted Net Profit Showed a Significant Adjusted EBITDA Experienced a Significant RMB million RMB million YOY Turnaround YOY Increase 454.2 Increased 398.0
Slide 23: CRO Financial Statistics
CRO Financial Statistics CRO Revenue RMB million Adjusted Gross profit RMB million 895 844.9 397 363.8 2022 2023 2022 2023 No. of CRO R&D Personnel Annual Revenue per CRO Personnel RMB thousand Increased 20% 1617 1155 731.5 609.3 2022 2023 2022 2023 www.vivabiotech.com 23
Slide 24: CDMO Financial Statistics
CDMO Financial Statistics Revenue of Langhua Pharmaceutical RMB million Adjusted Gross Profit of Langhua Pharmaceutical RMB million 1485 1311 433 389 2022 2023 2022 2023 www.vivabiotech.com 24
Slide 25: Revenue Classifications of Principal Activities
Revenue Classifications of Principal Activities As at December 31, 2023 CDMO and commercialization Drug discovery services Total services Types of goods or services RMB’000 RMB’000 RMB’000 Revenue from non-investees Full-time-equivalent (FTE) 637,400 - 637,400 Fee-for-service (FFS) 141,942 23,490 16
Slide 26: Items Measured at Fair Value with Changes in Fair Value Recognised in Profit or Loss
Items Measured at Fair Value with Changes in Fair Value Recognised in Profit or Loss The movements in the carrying value of unlisted investments at FVTPL for the Reporting Period are as follows： RMB’000 January 1, 2022 1,246,730 Acquired 70,748 Recognized from SFE revenue 61,016 Gain on fair value c
Slide 27: Appendix: Adjusted Non-IFRS Net Profit
APPENDIX: Adjusted Non-IFRS Net Profit 2023FY 2023H1 2022FY 2022H1 2021FY RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 Net Profit/ (Loss) -99,790 13,659 -504,220 -85,220 300,560 Add: Fair value gain on financial liabilities at fair -174,323 -10,050 -10,050 -143,590 value through profit or loss (“FVTPL”)
Slide 28: Part 3: Future Strategies
Viva PART 3: Future Strategies
Slide 29: Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service
Improve Capacity Building for Front-end Projects, Continue to Expand the Whole Industry Chain Service Downstream To Establish an Open and Cooperative Platform and a Early-stage Win-win Ecosystem for Global Biopharmaceutical Innovators pre-clinical service Raise technology barriers and expand servi
Slide 30: Q&A Session
Viva Q&A Session
Slide 31: Thank You
Viva Biotech Holdings THANK YOU！ No.735, Ziping Road, Pudong New Ir @vivabiotech.com Area, Shanghai 201318, China —— Tel: +86 21 6089 3288 E-mail: info@vivabiotech.com www.vivabiotech.com